Mediclinic International PLC Announcement in respect of MPILO arrangements (9984J)

TIDMMDC

RNS Number : 9984J

Mediclinic International PLC

16 September 2016

Mediclinic International plc

(Incorporated in England and Wales)

Company Number: 08338604

LSE Share Code: MDC

JSE Share Code: MEI

NSX Share Code: MEP

ISIN: GB00B8HX8Z88

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

16 September 2016

MEDICLINIC ANNOUNCEMENT IN RESPECT OF MPILO ARRANGEMENTS

During 2005 Mediclinic International (RF) Proprietary Limited (previously Mediclinic International Limited ("Mediclinic SA") implemented a black ownership initiative with MP1 Investment Holdings Proprietary Limited (previously Circle Capital Ventures Proprietary Limited) ("MP1") and Phodiso Holdings Limited ("Phodiso") (collectively, the "Strategic Black Partners").

Following completion in February 2016 of Mediclinic SA's combination with the Company (the "Combination"), the Company today announces that it has entered into arrangements with the Strategic Black Partners to formalise the basis on which the Strategic Black Partners hold their shares in the Company. These are in the same form in all material aspects as the arrangements in existence prior to the Combination. However, the Company now receives the direct benefit of the lock-in arrangements described below.

The arrangements that originally applied to the holdings of the Strategic Black Partners in relation to their shares in Mediclinic SA before completion of the Combination continue to apply to their holdings of shares in the Company such that:

-- in the case of the 24,582,960 shares held by Phodiso through its subsidiary Mpilo Investment Holdings 2 (RF) Proprietary Limited ("Mpilo 2"), representing approximately 3.33% of the Company's issued share capital, disposals of such shares are restricted until 31 December 2018; and

-- in the case of the 10,958,206 shares held by MP1 through its subsidiary Mpilo 1 Newco (RF) Proprietary Limited ("Mpilo 1"), representing approximately 1.49% of the Company's issued share capital, disposals of such shares are restricted until 31 December 2019.

The arrangements also contain pre-emptive rights in favour of the Company which provide that, if any of the shares in the Company or shares in one of the Strategic Black Partners' Mediclinic holding companies are to be offered for sale, the Company will be offered the opportunity to purchase such shares or to nominate another person to purchase such shares, in each case, at a discounted price of, approximately, in relation to the Mpilo 1 shares, 5% to the then market value and, in relation to the Mpilo 2 shares, 10%. Any exercise of a right to purchase such shares by the Company itself would require the approval of its shareholders.

Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom

Website: www.mediclinic.com

Corporate broker: Morgan Stanley & Co International plc

JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

For further information please contact:

Mediclinic International plc

James Arnold, Head of Investor Relations

[e-mail]

Capita Company Secretarial Services Limited

Victoria Dalby

[phone]

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCQELFFQKFLBBB

(END) Dow Jones Newswires

September 16, 2016 05:00 ET (09:00 GMT)